Anand Bhaskar 4
4 · REATA PHARMACEUTICALS INC · Filed Jun 16, 2023
Insider Transaction Report
Form 4
Anand Bhaskar
VP, Chief Accounting Officer
Transactions
- Sale
Class A common stock
2023-06-14$102.11/sh−2,343$239,248→ 24,898 total - Exercise/Conversion
Class A common stock
2023-06-14$27.32/sh+1,562$42,674→ 27,241 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-06-14−1,562→ 23,438 totalExercise: $27.32Exp: 2032-01-03→ Class A common stock (1,562 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $101.9841 to $102.52 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.